Tourmaline Bio
TRML
TRML was delisted on the 27th of October, 2025.
92 hedge funds and large institutions have $541M invested in Tourmaline Bio in 2024 Q3 according to their latest regulatory filings, with 21 funds opening new positions, 26 increasing their positions, 27 reducing their positions, and 13 closing their positions.
99% more capital invested
Capital invested by funds: $272M → $541M (+$269M)
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
62% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 13
11% more call options, than puts
Call options by funds: $262K | Put options by funds: $236K
10% more funds holding
Funds holding: 84 → 92 (+8)
0.44% less ownership
Funds ownership: 82.47% → 82.03% (-0.44%)
4% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$8.5M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
+$5.65M |
| 3 |
Pictet Asset Management
Carouge,
Switzerland
|
+$4.12M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$2.4M |
| 5 |
State Street
Boston,
Massachusetts
|
+$1.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$3.7M |
| 2 |
BOCH
Blue Owl Capital Holdings
New York
|
-$3.09M |
| 3 |
EP
Eversept Partners
New York
|
-$2.01M |
| 4 |
Two Sigma Investments
New York
|
-$2M |
| 5 |
SCM
Suvretta Capital Management
New York
|
-$1.61M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
AGM
101
Alpine Global Management
New York
| – | -$291K | -22,648 | Closed |
|
102
State of Wisconsin Investment Board
Madison,
Wisconsin
| – | -$150K | -11,686 | Closed |
|
103
Janus Henderson Group
London,
United Kingdom
| – | -$148K | -11,500 | Closed |
|
104
Simplex Trading
Chicago,
Illinois
| – | -$1.74K | -104 | Closed |
|
105
Carson Wealth (CWM LLC)
Omaha,
Nebraska
| – | +$33 | +2 | +22% |
|
TRML Hedge Fund Activity: Q3 2024 in Review
92 of the 6,965 institutional investors tracked by Wall St. Rank reported a position in Tourmaline Bio (TRML) for Q3 2024, worth a combined $541M — up 99% from $272M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TRML positions and 13 closed out — a net gain of 8 holders — while 26 added to existing stakes and 27 trimmed.
The largest buyer was Millennium Management, opening a new position worth an estimated $8.5M. The largest seller was Fidelity Investments, cutting an estimated $3.7M.
- 92 institutional investors held Tourmaline Bio (TRML) as of Q3 2024, up from 84 in Q2 2024.
- Funds reported $541M of Tourmaline Bio stock for Q3 2024, up 99% quarter-over-quarter.
- 21 funds opened new Tourmaline Bio positions in Q3 2024 and 13 closed out, a net change of +8 holders.
- The largest Tourmaline Bio buyer in Q3 2024 was Millennium Management, an estimated $8.5M added.
- The largest Tourmaline Bio seller in Q3 2024 was Fidelity Investments, an estimated $3.7M sold.
Based on aggregated 13F filings for Q3 2024.